China’s Hua Medicine Licenses Worldwide Rights To Roche Diabetes Compound, More Deals On The Way
This article was originally published in PharmAsia News
Chinese startup Hua Medicine kicks off its in-licensing strategy with an IND-ready glucokinase activator from Roche.
You may also be interested in...
Ascletis Opens Its $100 Million Wallet - Breaks Ground On China Facility, Sets Sights On In-Licensing
HANGZHOU, China - U.S.-China hybrid Ascletis Inc. is putting some of its $100 million Series A funding to immediate use, breaking ground Oct. 20 on a facility in Zhenjiang Province that will house its China headquarters and R&D center
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs